Allergan to pay Editas $90m for development of CRISPR eye treatment – Life Sciences Intellectual Property Review (subscription)
KC Register |
Allergan to pay Editas $90m for development of CRISPR eye treatment
Life Sciences Intellectual Property Review (subscription) Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology. CRISPR is a tool that can be programmed to target specific stretches of genetic code and … Editas Medicine Inc – Receive News & Ratings Daily The Editas Medicine Inc (EDIT) Shares Gap Down After Insider Selling Editas Medicine Inc (NASDAQ:EDIT) stock price target increased to $27.14, released a research note earlier today by … |
